Argent BioPharma Ltd NPV (DI)

Sell:0.00pBuy:0.00pNo change

Prices delayed by at least 15 minutes
Sell:0.00p
Buy:0.00p
Change:No change
Prices delayed by at least 15 minutes
Sell:0.00p
Buy:0.00p
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.

Key people

Roby Reuven Zomer
Chief Executive Officer, Managing Director, Executive Director
Yifat Steuer
Deputy Chief Executive Officer, Chief Operating Officer
Igor Bluvstein
Chief Financial Officer
Robert Clements
Chief Commercial Officer
Rowan Harland
Company Secretary
Gary Hermon
Non-Executive Director
Daniel Robinson
Non-Executive Director
Click to see more

Key facts

  • EPIC
    RGT
  • Location
    Australia
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    AU0000326647
  • Market cap
    GBX 0.00
  • Employees
    -
  • Shares in issue
    54.27m
  • Exchange
    Australian Stock Exchange Ltd
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.